Newron Pharmaceuticals SPA: Parkinson Disease trials

The registry lists 16 Parkinson Disease studies with Newron Pharmaceuticals SPA as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 4Phase 2 6Phase 3 8No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study on Tolerability of Repeat i.c.v. Administration of sNN0031 Infusion Solution in Patients With PDTerminatedNCT02408562Phase 1/2
• A Study With an Increased Dose Step in Patients That Have Previously Received Placebo or sNN0031.TerminatedNCT01829867Phase 1
• A Follow-up Study on Safety and Tolerability of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's DiseaseCompletedNCT01807338
• 18-month Study of Long-term Efficacy & Safety of Safinamide as add-on Therapy in Patients With Mid-late Stage PDCompletedNCT01286935Phase 3
• A Study to Evaluate Safinamide's Effect on Dopamine and Serotonin's Availability by Using Brain ImagingTerminatedNCT01264861Phase 2
• A Trial to Explore the Potential Benefit of Safinamide on Cognitive Impairment Associated With Parkinson's DiseaseCompletedNCT01211587Phase 2
• Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's DiseaseCompletedNCT01187966Phase 3
• Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease SubjectsCompletedNCT01113320Phase 2
• MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)TerminatedNCT01028586Phase 3
• A Study to Assess the Effect of Safinamide on Levodopa PharmacokineticsCompletedNCT01026428Phase 1/2
• A Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Parkinson's DiseaseCompletedNCT00866502Phase 1/2
• Open-Label Trial to Determine the Long-Term Safety of Safinamide in Parkinson's Disease PatientsTerminatedNCT00865579Phase 3
• Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine AgonistCompletedNCT00643045Phase 3
• Safinamide as Add-On Therapy in Patients With Early Idiopathic Parkinson's Disease Treated With a Stable Dose of a Single Dopamine Agonist (12 Month Extension)CompletedNCT00642889Phase 3
• Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to LevodopaCompletedNCT00627640Phase 3
• MOTION, Safinamide in Early IPD, as add-on to Dopamine AgonistCompletedNCT00605683Phase 3